| Literature DB >> 32611221 |
Osamu Kurihara1, Masamichi Takano2, Erika Yamamoto1, Taishi Yonetsu3, Tsunekazu Kakuta4, Tsunenari Soeda5, Bryan P Yan6, Filippo Crea7, Takumi Higuma8, Shigeki Kimura9, Yoshiyasu Minami10, Tom Adriaenssens11, Niklas F Boeder12, Holger M Nef12, Chong Jin Kim13, Vikas Thondapu1, Hyung Oh Kim1, Michele Russo1, Tomoyo Sugiyama1, Francesco Fracassi1, Hang Lee14, Kyoichi Mizuno15, Ik-Kyung Jang1,13.
Abstract
Background Seasonal variations in acute coronary syndromes (ACS) have been reported, with incidence and mortality peaking in the winter. However, the underlying pathophysiology for these variations remain speculative. Methods and Results Patients with ACS who underwent optical coherence tomography were recruited from 6 countries. The prevalence of the 3 most common pathologies (plaque rupture, plaque erosion, and calcified plaque) were compared between the 4 seasons. In 1113 patients with ACS (885 male; mean age, 65.8±11.6 years), the rates of plaque rupture, plaque erosion, and calcified plaque were 50%, 39%, and 11% in spring; 44%, 43%, and 13% in summer; 49%, 39%, and 12% in autumn; and 57%, 30%, and 13% in winter (P=0.039). After adjusting for age, sex, and other coronary risk factors, winter was significantly associated with increased risk of plaque rupture (odds ratio [OR], 1.652; 95% CI, 1.157-2.359; P=0.006) and decreased risk of plaque erosion (OR, 0.623; 95% CI, 0.429-0.905; P=0.013), compared with summer as a reference. Among patients with rupture, the prevalence of hypertension was significantly higher in winter (P=0.010), whereas no significant difference was observed in the other 2 groups. Conclusions Seasonal variations in the incidence of ACS reflect differences in the underlying pathobiology. The proportion of plaque rupture is highest in winter, whereas that of plaque erosion is highest in summer. A different approach may be needed for the prevention and treatment of ACS depending on the season of its occurrence. Registration URL: https://www.clinicaltrials.gov. Unique identifier: NCT03479723.Entities:
Keywords: optical coherence tomography; plaque erosion; plaque rupture; season
Year: 2020 PMID: 32611221 PMCID: PMC7670515 DOI: 10.1161/JAHA.119.015579
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Figure 1Optical coherence tomography images of 3 plaque pathologies.
Plaque rupture was defined by the presence of fibrous cap discontinuity with a communication between the lumen and the inner core of a plaque or with a cavity formation within the plaque. Plaque erosion was defined as a culprit plaque with an intact fibrous cap with or without attached thrombus. Calcified plaque was defined by the presence of superficial substantive calcium at the culprit site without evidence of ruptured lipid plaque.
Baseline Characteristics
| Characteristic | Spring | Summer | Autumn | Winter |
|
|---|---|---|---|---|---|
| (n=284) | (n=243) | (n=290) | (n=296) | ||
| Age, y | 66.3±11.9 | 65.5±11.2 | 65.4±11.6 | 65.8±11.6 | 0.773 |
| Sex, male | 228 (80) | 193 (79) | 233 (80) | 231 (78) | 0.892 |
| Hypertension | 192 (68) | 143 (59) | 184 (63) | 218 (74) | 0.002 |
| Dyslipidemia | 206 (73) | 164 (67) | 207 (71) | 219 (74) | 0.397 |
| Diabetes mellitus | 92 (32) | 89 (37) | 77 (27) | 101 (34) | 0.075 |
| CKD | 45 (16) | 41 (17) | 57 (20) | 60 (20) | 0.457 |
| Smoking history | 166 (59) | 154 (63) | 179 (62) | 187 (63) | 0.609 |
| Current | 107 (38) | 100 (41) | 121 (42) | 119 (40) | 0.865 |
| Past | 59 (21) | 54 (22) | 58 (20) | 68 (23) | |
| Previous MI | 21 (7) | 21 (9) | 13 (4) | 24 (8) | 0.223 |
| Previous PCI | 22 (8) | 21 (9) | 18 (6) | 28 (9) | 0.515 |
| Clinical presentation | 0.106 | ||||
| ST‐segment–elevation MI | 160 (56) | 118 (49) | 159 (55) | 177 (60) | |
| Non–ST‐segment–elevation MI | 98 (35) | 87 (36) | 99 (34) | 91 (31) | |
| Unstable angina pectoris | 26 (9) | 38 (15) | 32 (11) | 28 (9) | |
| Medication on admission | |||||
| Statin | 54 (19) | 54 (22) | 54 (19) | 56 (19) | 0.265 |
| ACE‐I/ARB | 72 (25) | 57 (23) | 67 (23) | 84 (28) | 0.063 |
| Beta blockers | 40 (14) | 24 (10) | 34 (12) | 33 (11) | 0.195 |
| Calcium channel blocker | 65 (23) | 52 (21) | 59 (20) | 75 (25) | 0.067 |
| Aspirin | 44 (15) | 40 (16) | 52 (18) | 42 (14) | 0.409 |
| Laboratory data | |||||
| Hb, g/dL | 13.9±2.0 | 14.0±2.0 | 14.0±1.8 | 14.1±1.7 | 0.501 |
| T‐cholesterol level, mg/dL | 188.8±41.2 | 191.9±41.3 | 190.4±45.7 | 196.3±41.0 | 0.196 |
| LDL‐C level, mg/dL | 123.7±41.4 | 124.7±39.6 | 122.6±43.3 | 127.9±41.1 | 0.456 |
| HDL‐C level, mg/dL | 46.1±13.7 | 45.7±12.4 | 47.1±14.9 | 47.6±13.7 | 0.369 |
| TG level, mg/dL | 127.3±104.1 | 126.8±96.6 | 123.5±98.9 | 125.0±90.9 | 0.970 |
| Hs‐CRP level, mg/dL | 0.78±2.09 | 0.64±1.81 | 0.70±1.85 | 0.71±1.63 | 0.904 |
| HbA1c, % | 6.2±1.3 | 6.3±1.3 | 6.1±1.3 | 6.2±1.1 | 0.485 |
| Creatinine, mg/dL | 1.02±1.22 | 0.96±0.92 | 1.04±1.09 | 1.12±1.43 | 0.490 |
| eGFR, mL/min per 1.73 m2 | 93.2±36.2 | 117.4±283.1 | 99.1±130.3 | 98.3±118.4 | 0.359 |
| Peak CK, IU | 1877±2350 | 1851±2301 | 1882±2299 | 1761±2130 | 0.922 |
| Peak CKMB, IU | 188.2±222.7 | 192.4±240.1 | 192.2±251.7 | 179.1±220.5 | 0.901 |
| Temperature | |||||
| Maximum, °C | 17.7±6.3 | 29.1±4.2 | 21.6±6.5 | 10.3±5.1 | <0.001 |
| Minimum, °C | 8.0±6.3 | 20.8±3.8 | 13.2±6.8 | 1.3±4.9 | <0.001 |
Values are number (percentage) or mean±SD. ACE‐I indicates angiotensin converting enzyme inhibitors; ARB, angiotensin II receptor blockers; CK, creatine kinase; CKD, chronic kidney disease; CKMB, creatine kinase MB; eGFR, estimated glomerular filtration rate; Hb, hemoglobin; HbA1c, hemoglobin A1c; HDL‐C, high‐density lipoprotein cholesterol; Hs‐CRP, high sensitivity C‐reactive protein; LDL‐C, low‐density lipoprotein cholesterol; MI, myocardial infarction; PCI, percutaneous coronary intervention; T‐cholesterol, total cholesterol; and TG, triglyceride.
indicate statistically significant.
Figure 2Overall proportion of plaque rupture, plaque erosion, and calcified plaque.
Plaque rupture was diagnosed in 561 patients (50%), plaque erosion in 417 patients (38%), and calcified plaque in 135 patients (12%).
Figure 3Proportion of plaque rupture, plaque erosion, and calcified plaque in each season.
The proportion of culprit lesion characteristics were significantly different between the 4 seasons (P=0.039). The highest proportion of plaque rupture was in winter and the lowest in summer. In contrast, the highest proportion of plaque erosion was in summer and the lowest in winter.
Optical Coherence Tomography Findings
| Spring | Summer | Autumn | Winter |
| |
|---|---|---|---|---|---|
| (n=284) | (n=243) | (n=290) | (n=296) | ||
| Lesion characteristics | |||||
| Plaque rupture | 143 (50) | 106 (44) | 143 (49) | 169 (57) | 0.039 |
| Plaque erosion | 111 (39) | 105 (43) | 113 (39) | 88 (30) | |
| Calcified plaque | 30 (11) | 32 (13) | 34 (12) | 39 (13) | |
| Qualitative assessment | |||||
| Lipid rich plaque | 179 (63) | 147 (60) | 174 (60) | 194 (66) | 0.498 |
| TCFA | 97 (34) | 74 (30) | 89 (31) | 115 (39) | 0.118 |
| Macrophage | 191 (67) | 155 (64) | 175 (60) | 210 (71) | 0.046 |
| Cholesterol crystal | 67 (24) | 48 (20) | 51 (18) | 55 (19) | 0.292 |
| Calcification | 119 (42) | 94 (39) | 133 (46) | 147 (50) | 0.057 |
| Thrombus | 235 (83) | 200 (82) | 234 (81) | 239 (81) | 0.934 |
| White | 125 (53) | 94 (47) | 109 (47) | 103 (43) | 0.428 |
| Red | 64 (27) | 50 (25) | 64 (27) | 64 (27) | |
| Mix | 46 (20) | 56 (28) | 61 (26) | 72 (30) | |
| Quantitative assessment | |||||
| Minimum fibrous cap thickness, μm | 87.0±55.4 | 92.0±51.3 | 83.5±44.5 | 86.0±92.5 | 0.689 |
| Max lipid arc, ° | 301.9±65.9 | 300.2±65.9 | 304.5±72.4 | 309.5±64.0 | 0.593 |
Values are presented as number (percentage) or mean±SD. TCFA indicates thin cap fibroatheroma.
indicate statistically significant.
Figure 4Comparison of temperature among 3 culprit lesion types.
The lowest maximum and minimum temperatures were observed among patients with plaque rupture.
Figure 5Prevalence of hypertension in each season among 3 culprit types.
The prevalence of hypertension was highest in winter only in patients with plaque rupture, whereas the prevalence of hypertension was similar in other seasons among patients with plaque erosion or calcified plaque.
Proportion of Pathogenesis Between Men and Women
| All | Spring | Summer | Autumn | Winter |
| |
|---|---|---|---|---|---|---|
| (n=1113) | (n=284) | (n=243) | (n=290) | (n=296) | ||
| Men, n=885 | 0.999 | |||||
| Lesion characteristics | 228 | 193 | 233 | 231 | ||
| Plaque rupture | 444 (50) | 115 (50) | 83 (43) | 114 (49) | 132 (57) | 0.115 |
| Plaque erosion | 334 (38) | 88 (39) | 84 (44) | 92 (39) | 70 (30) | |
| Calcified plaque | 107 (12) | 25 (11) | 26 (13) | 27 (12) | 29 (13) | |
| Women, n=228 | ||||||
| Lesion characteristics | 56 | 50 | 57 | 65 | ||
| Plaque rupture | 117 (51) | 28 (50) | 23 (46) | 29 (51) | 37 (57) | 0.698 |
| Plaque erosion | 83 (37) | 23 (41) | 21 (42) | 21 (37) | 18 (28) | |
| Calcified plaque | 28 (12) | 5 (9) | 6 (12) | 7 (12) | 10 (15) | |
Values are presented as number (percentage).
Logistic Regression Analyses for Each Pathogenesis
| Variable | Unadjusted |
| Adjusted |
| ||
|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | |||
| Plaque rupture | ||||||
| Age | 1.001 | 0.991–1011 | 0.843 | 1.002 | 0.991–1.014 | 0.718 |
| Sex (male) | 0.955 | 0.714–1.278 | 0.758 | 1.025 | 0.741–1.418 | 0.882 |
| Hypertension | 1.008 | 0.787–1.293 | 0.947 | 0.929 | 0.710–1.215 | 0.590 |
| Dyslipidemia | 1.107 | 0.854–1.437 | 0.443 | 0.914 | 0.686–1.218 | 0.541 |
| LDL‐C | 1.005 | 1.002–1.008 | <0.001 | 1.006 | 1.003–1.009 | <0.001 |
| Diabetes mellitus | 1.123 | 0.873–1.444 | 0.366 | 1.121 | 0.859–1.462 | 0.400 |
| CKD | 1.175 | 0.866–1.594 | 0.300 | 1.351 | 0.967–1.887 | 0.078 |
| Smoking | 0.902 | 0.708–1.149 | 0.404 | 0.857 | 0.652–1.128 | 0.271 |
| Season classification | ||||||
| Summer (reference) | ||||||
| Spring | 1.311 | 0.929–1.849 | 0.123 | 1.357 | 0.949–1.942 | 0.095 |
| Autumn | 1.257 | 0.893–1.771 | 0.190 | 1.296 | 0.907–1.852 | 0.155 |
| Winter | 1.720 | 1.221–2.422 | 0.002 | 1.652 | 1.157–2.359 | 0.006 |
| Plaque erosion | ||||||
| Age | 0.981 | 0.970–0.991 | <0.001 | 0.985 | 0.973–0.996 | 0.010 |
| Sex (male) | 1.059 | 0.783–1.432 | 0.710 | 0.956 | 0.681–1.341 | 0.793 |
| Hypertension | 0.735 | 0.570–0.948 | 0.018 | 0.877 | 0.666–1.155 | 0.349 |
| Dyslipidemia | 0.857 | 0.656–1.120 | 0.259 | 0.877 | 0.651–1.181 | 0.386 |
| LDL‐C | 0.999 | 0.996–1.002 | 0.451 | 0.998 | 0.994–1.001 | 0.161 |
| Diabetes mellitus | 0.718 | 0.551–0.936 | 0.014 | 0.794 | 0.600–1.051 | 0.107 |
| CKD | 0.469 | 0.331–0.663 | <0.001 | 0.481 | 0.328–0.705 | <0.001 |
| Smoking | 1.177 | 0.915–1.513 | 0.204 | 1.087 | 0.816–1.447 | 0.568 |
| Season classification | ||||||
| Summer (reference) | ||||||
| Spring | 0.843 | 0.595–1.194 | 0.337 | 0.885 | 0.614–1.278 | 0.515 |
| Autumn | 0.839 | 0.593–1.187 | 0.321 | 0.902 | 0.626–1.299 | 0.579 |
| Winter | 0.556 | 0.390–0.794 | 0.001 | 0.623 | 0.429–0.905 | 0.013 |
| Calcified plaque | ||||||
| Age | 1.045 | 1.027–1.063 | <0.001 | 1.037 | 1.016–1.058 | <0.001 |
| Sex (male) | 0.982 | 0.630–1.532 | 0.937 | 1.058 | 0.637–1.756 | 0.828 |
| Hypertension | 2.111 | 1.365–3.265 | 0.001 | 1.834 | 1.120–3.005 | 0.016 |
| Dyslipidemia | 1.109 | 0.739–1.664 | 0.618 | 1.634 | 1.030–2.592 | 0.037 |
| LDL‐C | 0.989 | 0.984–0.994 | <0.001 | 0.989 | 0.984–0.995 | <0.001 |
| Diabetes mellitus | 1.524 | 1.054–2.205 | 0.025 | 1.248 | 0.830–1.878 | 0.287 |
| CKD | 2.595 | 1.746–3.857 | <0.001 | 1.733 | 1.105–2.719 | 0.017 |
| Smoking | 0.893 | 0.619–1.289 | 0.545 | 1.170 | 0.757–1.807 | 0.480 |
| Season classification | ||||||
| Summer (reference) | ||||||
| Spring | 0.779 | 0.458–1.324 | 0.356 | 0.586 | 0.329–1.042 | 0.069 |
| Autumn | 0.876 | 0.523–1.467 | 0.614 | 0.635 | 0.359–1.123 | 0.119 |
| Winter | 1.001 | 0.606–1.653 | 0.998 | 0.810 | 0.474–1.387 | 0.443 |
CKD indicates chronic kidney disease; LDL‐C, low‐density lipoprotein cholesterol; and OR, odds ratio.
indicate statistically significant.